Home » Hot Sectors » Biotech Stocks » Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

ORLANDO, FL. – April 13th, 2019 – (CEOLIVE), Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer.

CEOLIVE has been covering Hemispherx for the two years and interviewed their CEO multiple times on both CEOLIVE and CEORoadshow to discuss the latest developments at the company.

According to the latest news from the company, Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical prostatectomy.

See full details of the study at ClinicalTrials.gov.
Read the full announcement at:

https://hemispherx.irpass.com/Hemispherx-Announces-Progress-Toward-Opening-of-Prostate-Cancer-Study-at-Roswell-Park-Comprehensive-

“This positive progress in commencing a new prostate cancer clinical trial is just one more step in our focused plan for R&D success,” said Hemispherx CEO Thomas K. Equels. “When our management team began three years ago, Hemispherx identified four significant steps we needed to take to make our company a success. First, raise the funds necessary to produce our drug candidate, Ampligen, for use in immuno-oncology clinical trials and other programs. Second, produce adequate supplies of Ampligen to conduct such trials. Third, initiate multiple immuno-oncology clinical trials. We have now accomplished each of these steps and are using Ampligen to treat cancers in clinical trials. Now is the time for us to seek out big pharma partners who share our excitement and enthusiasm for the potential of Ampligen. We believe that success in these trials will create the environment for that goal. Accomplishing success in R&D is based on such progress.”
About CEOLIVE.TV & CEORoadshow.com

CEOLIVE.TV provides in-depth news, commentary and interviews with public company CEO’s and their executive management teams.

CEORoadshow introduces public companies to thousands of active investors, fund managers, and financial institutions month after month.

Disclaimer / Disclosure

CEOLIVE content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to the accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOLIVE content and productions, or other investor relations materials and presentations are subject to change. Neither CEOLIVE nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information are provided for informational or entertainment purposes only.

It is also important to note, CEOLIVE is not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission or with any state securities regulatory authority. All statements and opinions expressed herein are those of the editors and contributors of CEOLIVE and are subject to change without notice. Any mention of a company at CEOLIVE is neither an offer nor solicitation of an offer to buy or sell any securities mentioned. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties. Furthermore, CEOLIVE has not independently verified such information provided within our publication.

Contact CEOLIVE

Mike Elliott
me@ceolive.com

Get Alerts for Latest Featured Stocks!
Signup today and receive the newest videos. We will never share or sell your email address.
I agree to have my personal information transfered to MailChimp ( more information )
Author: Mike Elliott

Login

Lost your password?